Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Conditions
- Recurrent Melanoma
- Stage IIIA Melanoma
- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IV Melanoma
Interventions
- OTHER: cytology specimen collection procedure
- DRUG: MEK 162 therapy or molecularly targeted therapy
- PROCEDURE: therapeutic procedure
- OTHER: laboratory biomarker analysis
- OTHER: quality-of-life assessment
Sponsor
Yale University
Collaborators